Verrica Pharmaceuticals
Verrica Pharmaceuticals, founded in 2013 and based in West Chester, Pennsylvania, specializes in developing medications for dermatological conditions.
Company Overview
Verrica Pharmaceuticals is a company specializing in the development of medications for skin diseases that require medical interventions. Founded in 2013, the company is headquartered in West Chester, Pennsylvania. Verrica Pharmaceuticals focuses on bringing innovative treatments to the dermatology market.
Lead Product: YCANTH™
YCANTH™ (cantharidin) is Verrica Pharmaceuticals' lead product. It is FDA-approved for the treatment of molluscum contagiosum in patients 2 years and older. This product has also received a permanent J-Code (J7354) from the Centers for Medicare and Medicaid Services, facilitating its use in clinical settings.
Product Pipeline
Verrica Pharmaceuticals is developing several products aimed at treating various dermatological conditions. VP-102 is in development for the treatment of common warts and external genital warts. Another product, VP-103, is being developed for the treatment of plantar warts, showcasing the company's commitment to addressing multiple skin diseases.
Collaborations and Licensing Agreements
In addition to its in-house developments, Verrica Pharmaceuticals has entered into a worldwide license agreement with Lytix Biopharma AS. This agreement aims to develop and commercialize VP-315, a treatment for dermatologic oncology conditions, broadening their scope in dermatological treatments beyond viral skin conditions.